WeedMD Inc. (TSXV:WMD) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical cannabis, is pleased to announce that the Company has appointed Dr. Jonas Vanderzwan as Medical Director and Chair of its Clinical Advisory Board. The Clinical Advisory Board will oversee all areas related to WeedMD’s medical research and development initiatives.

“We are honoured to have Dr. Vanderzwan join WeedMD. This is a strategic and important appointment for our patient base who are seeking standardized treatment options and more precise strain selection and dosing from their medical practitioner,” said Bruce Dawson-Scully, CEO, WeedMD. “An obstacle for many cannabis patients is the limited information coming from the medical community about cannabis use for specific ailments. Dr. Vanderzwan brings a wealth of experience, knowledge and the willingness to support patients and medical practitioners. He will also be participating in studies alongside leading institutions and their researchers from around the world.”


Dr. Vanderzwan is a physician with more than 15 years of primary care experience, and recently served as the lead physician of a London, Ontario based medical cannabis patient assessment clinic. Recognized in Southwestern Ontario as a cannabis educator and specialist, he has been actively providing medical staff with guidance on cannabis prescribing protocols, cannabis pharmacology, physiological effects and assessment tools. Dr. Vanderzwan is assisting with the establishment of an interest group at the Ontario Medical Association (OMA) with the purpose of continued advocacy and promotion of cannabis. He is also a member of the International Cannabinoid Research Society (ICRS), Canadian Consortium for the Investigation of Cannabinoids (CCIC), and International Association for Cannabinoid Medicines (IACM).

“As an enthusiastic proponent of prescribing medical cannabis as an alternative treatment option for patients, I’m pleased to be joining WeedMD – a licensed producer that takes great pride in its commitment to providing patients with responsible and innovative products and therapies – as well as encouraging sound practices in the seniors’ community,” said Dr. Vanderzwan. “While it is important that all the players in the cannabis industry take an active role in public education, it is also integral that we promote funding initiatives that aim to further establish cannabis as a legitimate medicine and WeedMD is actively pursuing such initiatives.”

WeedMD is committed to establishing credibility for cannabis in the medical community, and is in the process of securing a Health Canada Dealer’s License [read here].  A Dealer’s License will allow the Company to conduct R&D activities, store cannabis derivatives, process natural health products and export cannabis oils and concentrates to international markets.

About WeedMD Inc.

WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer and distributor of medical cannabis and cannabis oil under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 26,000 sq. ft. indoor facility in Aylmer, Ontario, and is awaiting its second-site cultivation license for its greenhouse facility located in Strathroy, Ontario, representing 610,000 sq. ft. or 14 acres under glass. WeedMD has entered into supply agreements in addition to strategic relationships with established cannabis brands.

The Company is focused on providing medical cannabis to the seniors’ market in Canada through its specialized and comprehensive platform. It is dedicated to educating healthcare practitioners and furthering public understanding of the role that medical cannabis plays – including as it pertains to regulatory requirements, indications and potential side effects.

For more information, access our investor presentation here and corporate video here.

Follow WeedMD:

Facebook: https://www.facebook.com/weedmd/
LinkedIn: https://www.linkedin.com/company-beta/5020743/
Twitter: https://twitter.com/WeedMD
Instagram: https://www.instagram.com/weedmd/

For further information, please contact:

WeedMD Inc.

Keith Merker, Chief Financial Officer
Tel: 519-765-2440 Ext. 222
Email: investor@weedmd.com

To learn more, visit us at www.weedmd.com

For Media Inquiries:

Marianella delaBarrera
Margin Communications & Public Relations
Tel: 416-897-6644
Email: marianella@marginpr.com

Forward-Looking Information

This press release contains forward-looking information based on current expectations. Statements about the date of trading of the Company’s common shares on the Exchange and final regulatory approvals, among others, are forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

___________________________________________________________________________________________________________________________________________
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

Click here to connect with WeedMD Inc. and receive an Investor’s Presentation.

Source: globenewswire.com

All five flavours of the Company’s KOIOS™ nootropic beverage product are now being carried by Jensen’s, a regional supermarket chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. This placement of KOIOS™ follows several other recent placements of the Company’s beverage products in regional supermarket chains across the United States as part of a strategy to passively build market share in specific geographical areas.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that the full range of five flavours of its KOIOS ™ nootropic beverages can now be purchased at all grocery stores operated by Jensen’s Foods (“Jensen’s”), a long-established family-owned grocery chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. In a press release dated February 19, 2021 the Company announced another chain-wide placement of KOIOS ™ nootropic beverages on the west coast of the United States with Market of Choice in Oregon. With this placement of KOIOS ™ in Jensen’s supermarkets, the Company’s beverage products are now carried in approximately 180 retail stores on the west coast, out of a total of more than 4,000 retail stores nationwide.

Keep reading... Show less

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less

It’s been just over a year since recreational cannabis was legalised in the Australian Capital Territory (ACT), home to the nation’s capital city of Canberra.

Announced on September 25, 2019, and brought into effect on January 31, 2020, the rules make it legal to possess and personally use small amounts of cannabis.

Keep reading... Show less

Pac Roots Cannabis Corp. (CSE: PACR) (“PacRoots” or the “Company”), announces the closing of its previously announced non-brokered private placement (see press release dated January 25, 2021).

Aggregate gross proceeds of $1,340,685.90 were raised through the issuance of 7,448,255 units (each a “Unit”). Each Unit consists of one common shares and one share purchase warrant. Each warrant is exercisable at a price of $0.30 per share until February 23, 2024.

Keep reading... Show less